ReviewAmerican journal of public health2019
Transnational Tobacco Companies and New Nicotine Delivery Systems.
Review in American journal of public health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Young Adult Responses to Peer Crowd-Based Targeting in E-cigarette Advertisements: An Experimental Study.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2023Trial
- Relative affordability of heated tobacco products and cigarettes: a cross-country comparative analysis of 55 countries.Harm reduction journal · 2026Article
- Vaping-related lung disease: a narrative review.Journal of thoracic disease · 2026Review
- Health advocacy strategies to influence policy-making on and regulation of new and emerging tobacco and nicotine products in Latin America and the Caribbean.Revista panamericana de salud publica = Pan American journal of public health · 2025Article
- Tobacco industry narratives of e-cigarette use in the UK: a qualitative framing analysis.Health promotion international · 2024Article
- Camel Crush pack inserts cross-promote Vuse menthol e-cigarettes ahead of impending menthol cigarette ban.Tobacco control · 2024Article
- Forecasting vaping health risks through neural network model prediction of flavour pyrolysis reactions.Scientific reports · 2024Article
- Pharmaceuticalisation as the tobacco industry's endgame.BMJ global health · 2024Article
- Tobacco Industry Engagement in the House of Commons Science and Technology Select Committee E-Cigarettes Inquiry.International journal of health policy and management · 2024Article
- Do Tobacco Companies Have an Incentive to Promote "Harm Reduction" Products?: The Role of Competition.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2023Article
- Article
- 'It's not what you'd term normal smoking': a qualitative exploration of language used to describe heated tobacco product use and associated user identity.Addiction (Abingdon, England) · 2023Article
- Subculture wars: The struggle for the vape industry.The British journal of sociology · 2023Article
- Vaping control in Nova Scotia: using research to catalyze change.Canadian journal of public health = Revue canadienne de sante publique · 2022Article
- Communication challenges of a tobacco addictiveness reduction policy.Tobacco induced diseases · 2021Article
- Unboxed: US Young Adult Tobacco Users' Responses to a New Heated Tobacco Product.International journal of environmental research and public health · 2020Article
- Adult Smokers' Awareness and Interest in Trying Heated Tobacco Products: Perspectives from Mexico, where HTPs and E-Cigarettes Are Banned.International journal of environmental research and public health · 2020Article
- Transformation of the Tobacco Industry.American journal of public health · 2019Article
- Electronic Cigarettes and Youth in the United States: A Call to Action (at the Local, National and Global Levels).Children (Basel, Switzerland) · 2019Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
3 authors.
Funding
Abstract
While the public health community has focused on the harm-reduction potential of new nicotine delivery systems (NNDSs) and, conversely, their potential for impeding overall efforts to prevent and reduce tobacco use, limited analysis has been conducted on the role of leading transnational tobacco companies (TTCs) in this rapidly growing market. Following aborted efforts during the 1980s and 1990s to develop reduced-risk products, TTCs have heavily invested in selected NNDS products since 2010 via acquisitions and internal research and development. This article catalogs and analyzes the patterns of investment in NNDSs by leading TTCs over time, and identifies differences in the companies' approaches to NNDS product acquisition and development in specific markets globally. This analysis raises important questions regarding the companies' intent, which appears to be to sustain, rather than replace, cigarette sales, and to increase their influence and credibility with respect to NNDS policy and regulation. We identify the need for greater public health vigilance and research to understand and respond to the increasingly significant role of NNDSs in TTCs' global business strategies, to ensure that NNDSs advance, rather than hinder, tobacco control efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.